Financial Lp Hrt Acquires 25,836 Shares of Shuttle Pharmaceuticals (NASDAQ:SHPH) Stock

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt acquired 25,836 shares of the firm’s stock in a transaction on Monday, June 29th. The stock was purchased at an average price of $3.44 per share, with a total value of $88,875.84. Following the purchase, the insider owned 71,842 shares in the company, valued at approximately $247,136.48. The trade was a 56.16% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Wednesday, July 1st, Financial Lp Hrt bought 3,959 shares of Shuttle Pharmaceuticals stock. The stock was acquired at an average price of $3.30 per share, for a total transaction of $13,064.70.
• On Tuesday, June 30th, Financial Lp Hrt bought 6,755 shares of Shuttle Pharmaceuticals stock. The stock was acquired at an average cost of $3.23 per share, with a total value of $21,818.65.

Shuttle Pharmaceuticals Trading Up 7.4%

Shares of SHPH opened at $3.65 on Friday. The stock has a 50 day moving average of $5.80 and a 200 day moving average of $10.64. The company has a market capitalization of $2.34 million, a price-to-earnings ratio of -0.08 and a beta of 0.29. Shuttle Pharmaceuticals Holdings, Inc. has a 12 month low of $2.90 and a 12 month high of $55.90.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.60 earnings per share (EPS) for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Shuttle Pharmaceuticals currently has an average rating of “Sell”.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in SHPH. Geode Capital Management LLC bought a new stake in Shuttle Pharmaceuticals in the 4th quarter valued at about $26,000. Boothbay Fund Management LLC purchased a new position in shares of Shuttle Pharmaceuticals in the fourth quarter worth about $37,000. Ikarian Capital LLC purchased a new position in shares of Shuttle Pharmaceuticals in the fourth quarter worth about $124,000. Finally, Connective Capital Management LLC purchased a new stake in shares of Shuttle Pharmaceuticals during the 3rd quarter valued at approximately $357,000. Institutional investors own 4.58% of the company’s stock.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .